EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta‐Analysis

Amey Joshi iD, Hafsa Arshad Azam Raja, Poulami Roy, Fakhar Latif, Rahul George Reji, Novonil Deb, Ryan K Mui, Ahmed Shady

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.16999 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Amey Joshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sparrow Hospital-Michigan State University, East Lansing, Michigan, USA. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Carbazoles, Hepatic Veins, Hypertension, Portal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Michigan State University, Michigan State University Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonselective beta‐blockers, such as propranolol and carvedilol, are used to prevent first decompensation in patients with clinically significant portal hypertension.

Methods

We performed a systematic literature search of English language articles from inception in PubMed, Medline, and Cochrane databases to compare the effect of carvedilol and propranolol on systemic and splanchnic hemodynamics. Mean differences were pooled using a random‐effect model, and a p ‐value of < 0.05 was considered statistically significant.

Results

Seven RCTs with a total of 351 patients were involved in the final analysis. Reduction in hepatic venous pressure gradient was significantly greater in the carvedilol group (MD = −0.76, 95% CI = −1.45 to −0.08; p = 0.03). Decrease in systemic vascular resistance and mean arterial pressure was significantly greater in the carvedilol group ([MD = −190.55, 95% CI = −307.5 to −73.58; p = 0.001] and [MD = −3.65, 95% CI = −5.94 to −1.36; p = 0.002], respectively). Decrease in cardiac output was greater in the propranolol group (MD = 0.92, 95% CI = 0.45–1.38; p = 0.004). Decrease in hepatic blood flow and right atrial pressure appeared to be greater in the propranolol group; however, this did not reach statistical significance ([MD = 0.13, 95% CI = −0.06 to 0.32; p = 0.17] and [MD = 0.28, 95% CI = −0.27 to 0.83; p = 0.32], respectively). Decrease in mean pulmonary arterial pressure appeared to be greater in the carvedilol group; however, this was not statistically significant (MD = −0.75, 95% CI = −1.60 to 0.10; p = 0.08). There was no difference in incidence of rebleeding, shortness of breath, hepatic encephalopathy, and hypotension between the two groups.

Conclusion

Carvedilol demonstrated a significantly greater reduction in HVPG, SVR, and MAP compared to propranolol, with no significant difference in adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsCarbazolesHepatic VeinsHypertension, PortalLiver CirrhosisPortal PressurePropanolaminesPropranololHumansCardiac OutputCarvedilolHemodynamicsSplanchnic CirculationTreatment OutcomeVascular Resistance

Stichwörter der Autor:innen

beta blockerscirrhosishemodynamichepatic venous pressure gradientmeta‐analysisportal hypertension

Substanzen

Adrenergic beta-AntagonistsCarbazolesCarvedilolPropanolaminesPropranolol

Autor:innen und Institutionen

  • Department of Internal Medicine, Sparrow Hospital-Michigan State University, East Lansing, Michigan, USA.
  • Rawalpindi Medical University, Rawalpindi, Pakistan.
  • North Bengal Medical College and Hospital, Siliguri, West Bengal, India.
  • Dow University of Health Sciences, Karachi, Sindh, Pakistan.
  • Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
  • Department of Gastroenterology, Sparrow Hospital-University of Michigan, East Lansing, Michigan, USA.

ORCID-Profile: Amey Joshi

Förderung

  • Michigan State University
  • Michigan State University Research Foundation

Zitieren

APA

Joshi, A., Raja, H. A. A., Roy, P., Latif, F., Reji, R. G., Deb, N., Mui, R. K., & Shady, A. (2025). Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta‐Analysis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16999

Vancouver

Joshi A, Raja HAA, Roy P, Latif F, Reji RG, Deb N, et al. Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta‐Analysis. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16999

BibTeX
@article{Joshi2025,
  author = {Joshi, Amey and Raja, Hafsa Arshad Azam and Roy, Poulami and Latif, Fakhar and Reji, Rahul George and Deb, Novonil and Mui, Ryan K and Shady, Ahmed},
  title = {Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta‐Analysis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.16999}
}
Kostenlos starten →